Abstract

Despite increasing use of targeted therapies to treat cancer, anemia remains a common complication of cancer therapy. Physician concerns about the safety of intravenous (IV) iron products and erythropoiesis-stimulating agents (ESAs) have resulted in many patients with cancer receiving no or suboptimal anemia therapy. In this article, we present 4 patient cases that illustrate both common and complex clinical scenarios. We first present a review of erythropoiesis and then describe our approach to cancer-associated anemia by identifying the contributing causes before selecting specific treatments. We summarize clinical trial data affirming the safety and efficacy of currently available IV iron products used to treat cancer-associated anemia and illustrate how we use commonly available laboratory tests to assess iron status during routine patient management. We compare adverse event rates associated with IV iron vs red cell transfusion and discuss using first-line IV iron monotherapy to treat anemic patients with cancer, which decreases the need for ESAs. A possible mechanism behind ESA-induced tumor progression is discussed. Finally, we review the potential of novel therapies such as ascorbic acid, prolyl hydroxylase inhibitors, activin traps, hepcidin, and bone morphogenetic protein antagonists in treating cancer-associated anemia.

REFERENCES

1.
U.S. Food and Drug Administration
. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Accessed 2 September 2019.
2.
Knight
K
,
Wade
S
,
Balducci
L
.
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
.
Am J Med
.
2004
;
116
(
suppl 7A
):
11S
-
26S
.
3.
Saint
A
,
Viotti
J
,
Borchiellini
D
, et al
.
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study
.
Support Care Cancer
.
2020
;
28
(
4
):
1639
-
1647
.
4.
Macciò
A
,
Madeddu
C
,
Gramignano
G
, et al
.
The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study
.
Haematologica
.
2015
;
100
(
1
):
124
-
132
.
5.
Ruiz-Schutz
VC
,
Gomes
LM
,
Mariano
RC
, et al
.
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials
.
Crit Rev Oncol Hematol
.
2019
;
141
:
163
-
173
.
6.
Straus
DJ
,
Testa
MA
,
Sarokhan
BJ
, et al
.
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies
.
Cancer
.
2006
;
107
(
8
):
1909
-
1917
.
7.
Crawford
J
,
Cella
D
,
Cleeland
CS
, et al
.
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
.
Cancer
.
2002
;
95
(
4
):
888
-
895
.
8.
Gilreath
JA
,
Stenehjem
DD
,
Rodgers
GM
.
Diagnosis and treatment of cancer-related anemia
.
Am J Hematol
.
2014
;
89
(
2
):
203
-
212
.
9.
McLean
E
,
Cogswell
M
,
Egli
I
,
Wojdyla
D
,
de Benoist
B
.
Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005
.
Public Health Nutr
.
2009
;
12
(
4
):
444
-
454
.
10.
National Cancer Institute, Cancer Therapy Evaluation Program
. Common Terminology Criteria for Adverse Events (CTCAE). Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 22 July 2019.
11.
Conroy
T
,
Desseigne
F
,
Ychou
M
, et al;
Groupe Tumeurs Digestives of Unicancer
;
PRODIGE Intergroup
.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
.
N Engl J Med
.
2011
;
364
(
19
):
1817
-
1825
.
12.
Schmid
P
,
Adams
S
,
Rugo
HS
, et al;
IMpassion130 Trial Investigators
.
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
.
N Engl J Med
.
2018
;
379
(
22
):
2108
-
2121
.
13.
Nienhuis
AW
,
Benz
EJ
Jr.
Regulation of hemoglobin synthesis during the development of the red cell (third of three parts)
.
N Engl J Med
.
1977
;
297
(
26
):
1430
-
1436
.
14.
Ganz
T
.
Erythrocytes and erythroblasts give up iron
.
Blood
.
2018
;
132
(
19
):
2004
-
2005
.
15.
Suzuki
N
,
Matsuo-Tezuka
Y
,
Sasaki
Y
, et al
.
Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2α concentrations in renal interstitial fibroblasts
.
Kidney Int
.
2018
;
94
(
5
):
900
-
911
.
16.
Kautz
L
,
Jung
G
,
Valore
EV
,
Rivella
S
,
Nemeth
E
,
Ganz
T
.
Identification of erythroferrone as an erythroid regulator of iron metabolism
.
Nat Genet
.
2014
;
46
(
7
):
678
-
684
.
17.
Arezes
J
,
Foy
N
,
McHugh
K
, et al
.
Erythroferrone inhibits the induction of hepcidin by BMP6
.
Blood
.
2018
;
132
(
14
):
1473
-
1477
.
18.
Jiang
X
,
Gao
M
,
Chen
Y
, et al
.
EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia
.
Blood Cells Mol Dis
.
2016
;
58
:
45
-
51
.
19.
Fillebeen
C
,
Wilkinson
N
,
Charlebois
E
,
Katsarou
A
,
Wagner
J
,
Pantopoulos
K
.
Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling
.
Blood
.
2018
;
132
(
17
):
1829
-
1841
.
20.
Muckenthaler
MU
,
Rivella
S
,
Hentze
MW
,
Galy
B
.
A red carpet for iron metabolism
.
Cell
.
2017
;
168
(
3
):
344
-
361
.
21.
Wrighting
DM
,
Andrews
NC
.
Interleukin-6 induces hepcidin expression through STAT3
.
Blood
.
2006
;
108
(
9
):
3204
-
3209
.
22.
Steinbicker
AU
,
Muckenthaler
MU
.
Out of balance--systemic iron homeostasis in iron-related disorders
.
Nutrients
.
2013
;
5
(
8
):
3034
-
3061
.
23.
Worthen
CA
,
Enns
CA
.
The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body
.
Front Pharmacol
.
2014
;
5
:
34
.
24.
Nai
A
,
Lidonnici
MR
,
Rausa
M
, et al
.
The second transferrin receptor regulates red blood cell production in mice
.
Blood
.
2015
;
125
(
7
):
1170
-
1179
.
25.
Fillebeen
C
,
Charlebois
E
,
Wagner
J
, et al
.
Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load
.
Blood
.
2019
;
133
(
4
):
344
-
355
.
26.
Nemeth
E
,
Tuttle
MS
,
Powelson
J
, et al
.
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
.
Science
.
2004
;
306
(
5704
):
2090
-
2093
.
27.
Steensma
DP
.
Clinical implications of clonal hematopoiesis
.
Mayo Clin Proc
.
2018
;
93
(
8
):
1122
-
1130
.
28.
Spivak
JL
.
Cancer-related anemia: its causes and characteristics
.
Semin Oncol
.
1994
;
21
(
2
):
3
-
8
.
29.
Ludwig
H
,
Van Belle
S
,
Barrett-Lee
P
, et al
.
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
.
Eur J Cancer
.
2004
;
40
(
15
):
2293
-
2306
.
30.
Noxon
V
,
Knopf
KB
,
Norris
LB
, et al
.
Tale of two erythropoiesis-stimulating agents: Utilization, dosing, litigation, and costs of darbepoetin and epoetin among South Carolina Medicaid-covered patients with cancer and chemotherapy-induced anemia
.
J Oncol Pract
.
2017
;
13
(
6
):
e562
-
e573
.
31.
Kuzminski
AM
,
Del Giacco
EJ
,
Allen
RH
,
Stabler
SP
,
Lindenbaum
J
.
Effective treatment of cobalamin deficiency with oral cobalamin
.
Blood
.
1998
;
92
(
4
):
1191
-
1198
.
32.
Wakeman
L
,
Al-Ismail
S
,
Benton
A
, et al
.
Robust, routine hematology reference ranges for healthy adults
.
Int J Lab Hematol
.
2007
;
29
(
4
):
279
-
283
.
33.
Goodnough
LT
.
Iron deficiency syndromes and iron-restricted erythropoiesis (CME)
.
Transfusion
.
2012
;
52
(
7
):
1584
-
1592
.
34.
Auerbach
M
,
Ballard
H
,
Trout
JR
, et al
.
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial
.
J Clin Oncol
.
2004
;
22
(
7
):
1301
-
1307
.
35.
Bastit
L
,
Vandebroek
A
,
Altintas
S
, et al
.
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
.
J Clin Oncol
.
2008
;
26
(
10
):
1611
-
1618
.
36.
Hedenus
M
,
Birgegård
G
,
Näsman
P
, et al
.
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
.
Leukemia
.
2007
;
21
(
4
):
627
-
632
.
37.
Pedrazzoli
P
,
Farris
A
,
Del Prete
S
, et al
.
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
.
J Clin Oncol
.
2008
;
26
(
10
):
1619
-
1625
.
38.
Jacobs
A
,
Worwood
M
.
Ferritin in serum. Clinical and biochemical implications
.
N Engl J Med
.
1975
;
292
(
18
):
951
-
956
.
39.
Coyne
D
.
Iron indices: what do they really mean?
Kidney Int Suppl
.
2006
;(
101
):
S4
-
S8
.
40.
Mast
AE
,
Blinder
MA
,
Gronowski
AM
,
Chumley
C
,
Scott
MG
.
Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations
.
Clin Chem
.
1998
;
44
(
1
):
45
-
51
.
41.
Henry
DH
,
Dahl
NV
,
Auerbach
MA
.
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron
.
Am J Hematol
.
2012
;
87
(
3
):
308
-
310
.
42.
Song
Andrew B
,
Kuter
David J
,
Al-Samkari
Hanny
.
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia [published online ahead of print 3 July 2020]
.
Am. J. Hematol
.
2020
;
doi:10.1002/ajh.25925
43.
Birgegård
G
,
Henry
D
,
Glaspy
J
,
Chopra
R
,
Thomsen
LL
,
Auerbach
M
.
A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: The PROFOUND trial
.
Pharmacotherapy
.
2016
;
36
(
4
):
402
-
414
.
44.
Steensma
DP
,
Sloan
JA
,
Dakhil
SR
, et al
.
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia
.
J Clin Oncol
.
2011
;
29
(
1
):
97
-
105
.
45.
Moretti
D
,
Goede
JS
,
Zeder
C
, et al
.
Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women
.
Blood
.
2015
;
126
(
17
):
1981
-
1989
.
46.
Stoffel
NU
,
Cercamondi
CI
,
Brittenham
G
, et al
.
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
.
Lancet Haematol
.
2017
;
4
(
11
):
e524
-
e533
.
47.
Auerbach
M
,
Pappadakis
JA
,
Bahrain
H
,
Auerbach
SA
,
Ballard
H
,
Dahl
NV
.
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia
.
Am J Hematol
.
2011
;
86
(
10
):
860
-
862
.
48.
DeLoughery
TG
,
Auerbach
M
.
Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study
.
Am J Hematol
.
2016
;
91
(
5
):
451
-
452
.
49.
Steinmetz
T
,
Tschechne
B
,
Harlin
O
, et al
.
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
.
Ann Oncol
.
2013
;
24
(
2
):
475
-
482
.
50.
Gilreath
JA
,
Makharadze
T
,
Boccia
RV
,
Krupa
A
,
Henry
DH
.
Efficacy and safety of ferric carboxymaltose injection in reducing anemia in patients receiving chemotherapy for non-myeloid malignancies: A phase 3, placebo-controlled study (IRON CLAD) [abstract]
.
Blood
2019
;
134
.
Abstract 3535
.
51.
Rodgers
GM
,
Gilreath
JA
.
The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy
.
Acta Haematol
.
2019
;
142
(
1
):
13
-
20
.
52.
Gilreath
JA
,
Stenehjem
DD
,
Rodgers
GM
.
Total dose iron dextran infusion in cancer patients: is it SaFe2+?
J Natl Compr Canc Netw
.
2012
;
10
(
5
):
669
-
676
.
53.
Ganz
T
.
Anemia of Inflammation
.
N Engl J Med
.
2019
;
381
(
12
):
1148
-
1157
.
54.
Jang
JH
,
Kim
Y
,
Park
S
, et al
.
Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective phase II pilot clinical trial in South Korea
.
Plos Med
.
2020
;
17
(
6
):
e1003091
.
55.
Bohlius
J
,
Bohlke
K
,
Castelli
R
, et al
.
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
.
J Clin Oncol
.
2019
;
37
(
15
):
1336
-
1351
.
56.
Bokemeyer
C
,
Aapro
MS
,
Courdi
A
, et al;
European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly
.
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
.
Eur J Cancer
.
2007
;
43
(
2
):
258
-
270
.
57.
Rodgers
GM
III
,
Becker
PS
,
Blinder
M
, et al
.
Cancer- and chemotherapy-induced anemia
.
J Natl Compr Canc Netw
.
2012
;
10
(
5
):
628
-
653
.
58.
Szebeni
J
,
Fishbane
S
,
Hedenus
M
, et al
.
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
.
Br J Pharmacol
.
2015
;
172
(
21
):
5025
-
5036
.
59.
Rampton
D
,
Folkersen
J
,
Fishbane
S
, et al
.
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
.
Haematologica
.
2014
;
99
(
11
):
1671
-
1676
.
60.
Avni
T
,
Bieber
A
,
Grossman
A
,
Green
H
,
Leibovici
L
,
Gafter-Gvili
A
.
The safety of intravenous iron preparations: systematic review and meta-analysis
.
Mayo Clin Proc
.
2015
;
90
(
1
):
12
-
23
.
61.
Drakesmith
H
,
Prentice
A
.
Viral infection and iron metabolism
.
Nat Rev Microbiol
.
2008
;
6
(
7
):
541
-
552
.
62.
Bowser
BA
,
Campeau
NG
,
Carr
CM
, et al
.
Incidental ferumoxytol artifacts in clinical brain MR imaging
.
Neuroradiology
.
2016
;
58
(
11
):
1087
-
1091
.
63.
Barton
JC
,
Barton
EH
,
Bertoli
LF
,
Gothard
CH
,
Sherrer
JS
.
Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation
.
Am J Med
.
2000
;
109
(
1
):
27
-
32
.
64.
Steensma
DP
,
Sasu
BJ
,
Sloan
JA
,
Tomita
DK
,
Loprinzi
CL
.
Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia
.
Blood
.
2015
;
125
(
23
):
3669
-
3671
.
65.
Bohlius
J
,
Wilson
J
,
Seidenfeld
J
, et al
.
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
.
J Natl Cancer Inst
.
2006
;
98
(
10
):
708
-
714
.
66.
Spivak
JL
,
Gascón
P
,
Ludwig
H
.
Anemia management in oncology and hematology
.
Oncologist
.
2009
;
14
(
suppl 1
):
43
-
56
.
67.
Bohlius
J
,
Schmidlin
K
,
Brillant
C
, et al
.
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
.
Lancet
.
2009
;
373
(
9674
):
1532
-
1542
.
68.
Tonia
T
,
Mettler
A
,
Robert
N
, et al
.
Erythropoietin or darbepoetin for patients with cancer
.
Cochrane Database Syst Rev
.
2012
;
12
:
CD003407
.
69.
Losem
C
,
Koenigsmann
M
,
Rudolph
C
.
Biosimilar Retacrit® (Epoetin Zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study
.
OncoTargets Ther
.
2017
;
10
:
1295
-
1305
.
70.
Trotta
F
,
Belleudi
V
,
Fusco
D
, et al
.
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
.
BMJ Open
.
2017
;
7
(
3
):
e011637
.
71.
Bohlius
J
,
Bohlke
K
,
Castelli
R
, et al
.
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
.
Blood Adv
.
2019
;
3
(
8
):
1197
-
1210
.
72.
Littlewood
TJ
,
Zagari
M
,
Pallister
C
,
Perkins
A
.
Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients
.
Oncologist
.
2003
;
8
(
1
):
99
-
107
.
73.
US Food and Drug Administration
. Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-erythropoiesis-stimulating-agents-esa-epoetin-alfa-marketed-procrit-epogen-darbepoetin. Accessed 31 October 2019.
74.
US Food and Drug Administration
. Drugs@FDA: FDA approved drug products. Label update 4/13/
2017
. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103951. Accessed 31 October 2019.
75.
Gascón
P
,
Nagarkar
R
,
Šmakal
M
, et al
.
A randomized, double-blind, placebo-controlled, phase III noninferiority study of the long-term safety and efficacy of darbepoetin alfa for chemotherapy-induced anemia in patients with advanced NSCLC
.
J Thorac Oncol
.
2020
;
15
(
2
):
190
-
202
.
76.
Vansteenkiste
J
,
Glaspy
J
,
Henry
D
, et al
.
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses
.
Lung Cancer
.
2012
;
76
(
3
):
478
-
485
.
77.
Glaspy
J
,
Crawford
J
,
Vansteenkiste
J
, et al
.
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
.
Br J Cancer
.
2010
;
102
(
2
):
301
-
315
.
78.
Aapro
M
,
Jelkmann
W
,
Constantinescu
SN
,
Leyland-Jones
B
.
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
.
Br J Cancer
.
2012
;
106
(
7
):
1249
-
1258
.
79.
Leyland-Jones
B
.
Erythropoiesis stimulating agents: a personal journey
.
J Natl Cancer Inst
.
2013
;
105
(
14
):
999
-
1001
.
80.
Lippi
G
,
Franchini
M
,
Favaloro
EJ
.
Thrombotic complications of erythropoiesis-stimulating agents
.
Semin Thromb Hemost
.
2010
;
36
(
5
):
537
-
549
.
81.
Pradeep
S
,
Huang
J
,
Mora
EM
, et al
.
Erythropoietin stimulates tumor growth via EphB4
.
Cancer Cell
.
2015
;
28
(
5
):
610
-
622
.
82.
Noren
NK
,
Lu
M
,
Freeman
AL
,
Koolpe
M
,
Pasquale
EB
.
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth
.
Proc Natl Acad Sci U S A
.
2004
;
101
(
15
):
5583
-
5588
.
83.
Khorana
AA
,
Francis
CW
,
Blumberg
N
,
Culakova
E
,
Refaai
MA
,
Lyman
GH
.
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
.
Arch Intern Med
.
2008
;
168
(
21
):
2377
-
2381
.
84.
Iqbal
N
,
Haider
K
,
Sundaram
V
, et al
.
Red blood cell transfusion and outcome in cancer
.
Transfus Apheresis Sci
.
2017
;
56
(
3
):
287
-
290
.
85.
Lee
J
,
Chin
JH
,
Kim
JI
,
Lee
EH
,
Choi
IC
.
Association between red blood cell transfusion and long-term mortality in patients with cancer of the esophagus after esophagectomy
.
Dis Esophagus
.
2018
;
31
(
2
):
86.
American Society of Hematology
.
ASH Statement in Support of Palliative Blood Transfusions in Hospice Setting
.
Published June 25, 2019. Available at: https://www.hematology.org/advocacy/policy-statements/2019/palliative-blood-transfusions-in-hospice. Accessed October 31, 2019
.
87.
Scharman
CD
,
Burger
D
,
Shatzel
JJ
,
Kim
E
,
DeLoughery
TG
.
Treatment of individuals who cannot receive blood products for religious or other reasons
.
Am J Hematol
.
2017
;
92
(
12
):
1370
-
1381
.
88.
Posluszny
JA
Jr.
,
Napolitano
LM
.
How do we treat life-threatening anemia in a Jehovah’s Witness patient?
Transfusion
.
2014
;
54
(
12
):
3026
-
3034
.
89.
Morgentaler
A
,
Caliber
M
.
Safety of testosterone therapy in men with prostate cancer
.
Expert Opin Drug Saf
.
2019
;
18
(
11
):
1065
-
1076
.
90.
Thavarajah
S
,
Choi
MJ
.
The use of erythropoiesis-stimulating agents in patients with CKD and cancer: A clinical approach
.
Am J Kidney Dis
.
2019
;
74
(
5
):
667
-
674
.
91.
Smith
RE
Jr.
,
Aapro
MS
,
Ludwig
H
, et al
.
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
.
J Clin Oncol
.
2008
;
26
(
7
):
1040
-
1050
.
92.
Singh
AK
,
Szczech
L
,
Tang
KL
, et al;
CHOIR Investigators
.
Correction of anemia with epoetin alfa in chronic kidney disease
.
N Engl J Med
.
2006
;
355
(
20
):
2085
-
2098
.
93.
Anampa
J
,
Haque
T
,
Murakhovskaya
I
, et al
.
Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer
.
Haematologica
.
2018
;
103
(
3
):
e98
-
e102
.
94.
Chuhjo
T
,
Yamazaki
H
,
Omine
M
,
Nakao
S
.
Danazol therapy for aplastic anemia refractory to immunosuppressive therapy
.
Am J Hematol
.
2008
;
83
(
5
):
387
-
389
.
95.
Townsley
DM
,
Dumitriu
B
,
Liu
D
, et al
.
Danazol treatment for telomere diseases
.
N Engl J Med
.
2016
;
374
(
20
):
1922
-
1931
.
96.
Guo
W
,
Bachman
E
,
Li
M
, et al
.
Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells
.
Aging Cell
.
2013
;
12
(
2
):
280
-
291
.
97.
Cervantes
F
,
Isola
IM
,
Alvarez-Larrán
A
,
Hernández-Boluda
JC
,
Correa
JG
,
Pereira
A
.
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
.
Ann Hematol
.
2015
;
94
(
11
):
1791
-
1796
.
98.
Sourabh
S
,
Bhatia
P
,
Jain
R
.
Favourable improvement in haematological parameters in response to oral iron and vitamin C combination in children with iron refractory iron deficiency anemia (IRIDA) phenotype
.
Blood Cells Mol Dis
.
2019
;
75
:
26
-
29
.
99.
Chiu
PF
,
Ko
SY
,
Chang
CC
.
Vitamin C affects the expression of hepcidin and erythropoietin receptor in HepG2 cells
.
J Ren Nutr
.
2012
;
22
(
3
):
373
-
376
.
100.
Sedighi
O
,
Makhlough
A
,
Janbabai
G
,
Neemi
M
.
Comparative study of intravenous iron versus intravenous ascorbic acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial
.
Nephrourol Mon
.
2013
;
5
(
4
):
913
-
917
.
101.
Attallah
N
,
Osman-Malik
Y
,
Frinak
S
,
Besarab
A
.
Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia
.
Am J Kidney Dis
.
2006
;
47
(
4
):
644
-
654
.
102.
Elalfy
MS
,
Saber
MM
,
Adly
AA
, et al
.
Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload
.
Eur J Haematol
.
2016
;
96
(
3
):
318
-
326
.
103.
Chen
N
,
Hao
C
,
Peng
X
, et al
.
Roxadustat for anemia in patients with kidney disease not receiving dialysis
.
N Engl J Med
.
2019
;
381
(
11
):
1001
-
1010
.
104.
Chen
N
,
Hao
C
,
Liu
BC
, et al
.
Roxadustat treatment for anemia in patients undergoing long-term dialysis
.
N Engl J Med
.
2019
;
381
(
11
):
1011
-
1022
.
105.
Jelkmann
W
.
Activin receptor ligand traps in chronic kidney disease
.
Curr Opin Nephrol Hypertens
.
2018
;
27
(
5
):
351
-
357
.
106.
Vadhan-Raj
S
,
Abonour
R
,
Goldman
JW
, et al
.
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
.
J Hematol Oncol
.
2017
;
10
(
1
):
73
.
107.
Meynard
D
,
Kautz
L
,
Darnaud
V
,
Canonne-Hergaux
F
,
Coppin
H
,
Roth
MP
.
Lack of the bone morphogenetic protein BMP6 induces massive iron overload
.
Nat Genet
.
2009
;
41
(
4
):
478
-
481
.
108.
Meynard
D
,
Vaja
V
,
Sun
CC
, et al
.
Regulation of TMPRSS6 by BMP6 and iron in human cells and mice
.
Blood
.
2011
;
118
(
3
):
747
-
756
.
109.
Canali
S
,
Wang
CY
,
Zumbrennen-Bullough
KB
,
Bayer
A
,
Babitt
JL
.
Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6
.
Am J Hematol
.
2017
;
92
(
11
):
1204
-
1213
.
110.
Babitt
JL
,
Huang
FW
,
Xia
Y
,
Sidis
Y
,
Andrews
NC
,
Lin
HY
.
Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance
.
J Clin Invest
.
2007
;
117
(
7
):
1933
-
1939
.
111.
Shi
X
,
Yang
J
,
Zhu
H
, et al
.
Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo
.
PLoS One
.
2013
;
8
(
8
):
e72673
.
You do not currently have access to this content.

Sign in via your Institution

Sign In